---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-144146"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:27:47.682315+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q1 net loss $22.8M, cash $236.4M; pipeline catalysts on track

## Summary
- Net loss $22.8M in Q1 2023 vs $9.9M in Q1 2022; R&D expenses $20.2M including $10M Mabwell upfront.
- Cash and equivalents $236.4M at March 31, 2023, up from $194.6M; funding expected into 2025.
- Bitopertin Phase 2 BEACON interim data at EHA June 9, 2023; topline from BEACON and AURORA by end 2023.
- DISC-0974 Phase 1b/2 in NDD-CKD and MF anemia; interim data expected by end of 2023.
- In-licensed anti-TMPRSS6 mAbs from Mabwell; Phase 1 trial planned for second half 2023.

## SEC filing metadata
- accession: 0001193125-23-144146
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/0001193125-23-144146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/d481241d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-144146
- JSON: https://secwatch.observer/filing/0001193125-23-144146.json
- Plain text: https://secwatch.observer/filing/0001193125-23-144146.txt

## Key facts
- Earnings Releases
  Disc Medicine, Inc. reported financial results for first quarter ending March 31, 2023.
  - Period: first quarter ending March 31, 2023
  - Result: reported results
  source text: Disc Medicine, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312523144146/0001193125-23-144146-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.